FindTrial
Sign In

V-fold rotation acupuncture point embedding combined with classical prescription clearing the upper coke and warming the lower coke in the treatment of metabolic syndrome and QOL-BREF quality of life evaluation

V-fold rotation acupuncture point embedding combined with classical prescription clearing the upper coke and warming the lower coke in the treatment of metabolic syndrome and QOL-BREF quality of life evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081802
Enrollment
Unknown
Registered
2024-03-12
Start date
2024-03-15
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

Group A (control group):Basic treatment in internal medicine
Group B (Observation 1 group):On the basis of group A, the classic formula "Huanglian Decoction and Huangqin Huashi Decoction" selected by the method of clearing the upper coke and warming the lower c
Group C (observation 2 groups):On the basis of group B, V-fold rotation acupuncture point embedding method was added.

Sponsors

Tianjin Binhai New Area Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1)Meets diagnostic criteria for metabolic syndrome. (2)TCM syndrome differentiation is obesity with upper heat and lower cold. (3) Age 18 years old or older, male or female. (4) Voluntarily complete the relevant examination and treatment items in the trial.

Exclusion criteria

Exclusion criteria: (1)Patients with severe heart disease, such as acute myocardial infarction, malignant arrhythmia, severe heart failure, obvious myocardial lesions. (2)Patients with other major systemic lesions such as severe respiratory failure, severe liver and kidney failure, advanced malignant tumors, severe infection, hyperthyroid crisis, diabetic ketoacidosis, grand mal seizures, mania, and severe hypopituitarism. (3)Those who have had major surgery and bleeding tendency in the past 4 weeks. (4)Women who are pregnant or preparing to become pregnant and who are lactating. (5)Those who are allergic to the drug components in the trial. (6)Those who have participated in other clinical trials in the past 1 month. (7)Those who are unable to communicate normally.

Design outcomes

Primary

MeasureTime frame
Waist circumference;hip circumference;Systolic blood pressure;diastolic blood pressure;Fasting blood glucose;2 hours postprandial blood glucose;Glycosylated hemoglobin ;Fasting insulin;2 hours postprandial insulin;Total cholesterol;Triglycerides;high-density lipoprotein cholesterol;Low-density lipoprotein cholesterol;C-reactive protein;Tumor necrosis factor a ;Interleukin 6;homocysteine;uric acid ;Score of The World Health Organization quality of life (?WHOQOL)? - BREF;Height body mass index;—

Countries

China

Contacts

Public ContactDing Huaiying

Tianjin Binhai New Area Hospital of Traditional Chinese Medicine

dinghuaiying@sina.com+86 138 2162 3072

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026